National Pension Service Raises Stake in Edwards Lifesciences Co. (NYSE:EW)

National Pension Service boosted its stake in Edwards Lifesciences Co. (NYSE:EW) by 9.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,584,579 shares of the medical research company’s stock after acquiring an additional 133,182 shares during the quarter. National Pension Service owned about 0.26% of Edwards Lifesciences worth $104,566,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Choreo LLC boosted its stake in shares of Edwards Lifesciences by 4.1% during the 1st quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock valued at $367,000 after buying an additional 153 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Edwards Lifesciences by 37.7% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 2,038 shares of the medical research company’s stock valued at $195,000 after buying an additional 558 shares in the last quarter. 9258 Wealth Management LLC boosted its stake in Edwards Lifesciences by 2.6% during the first quarter. 9258 Wealth Management LLC now owns 10,803 shares of the medical research company’s stock valued at $1,032,000 after buying an additional 274 shares in the last quarter. LCM Capital Management Inc bought a new position in Edwards Lifesciences during the first quarter valued at about $231,000. Finally, Empirical Finance LLC boosted its stake in Edwards Lifesciences by 3.4% during the first quarter. Empirical Finance LLC now owns 22,046 shares of the medical research company’s stock valued at $2,107,000 after buying an additional 732 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on EW. Evercore ISI decreased their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Barclays cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average price target of $75.67.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,250 shares of company stock worth $1,099,238. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 1.6 %

EW stock opened at $66.47 on Tuesday. The company has a market cap of $40.04 billion, a P/E ratio of 9.59, a PEG ratio of 3.77 and a beta of 1.12. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $67.87 and a 200-day moving average of $77.40.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.56% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.